Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$27,000.00
Epigenetic Combination Therapy in Xenografted Sporadic Microsatellite Instablity-high (MSI-H) Colorectal Cancers
FY 2024-25
Summary
Most human cancers exhibit drastic changes in the epigenetic landscape. This has led to the development of drugs that target epigenetic changes in cancers. These drugs have shown promising results in many types of cancer but have yet to be tested in colorectal cancer (CRC). 26,300 Canadians are diagnosed with colorectal cancer and 9,500 die from it every year making it a vital area of research. My project aims to test treatment combinations that specifically target the epigenetic pathway in a subtype of CRC that develops due to DNA methylation-induced gene silencing of key tumor-suppressor genes. I am culturing patient-derived organoids from samples of 10 human CRC patients to create a live CRC model in mice to test novel treatment options. I will compare tumor responses in mice treated with a combination of traditional chemotherapy and a novel epigenetic treatment to those receiving either chemotherapy alone or epigenetic treatments alone. We expect to see that combinatorial treatments will be more effective than either treatment alone. My project thus aims to expand treatment options for CRC, potentially paving the way for personalized medicine approaches.The use of organoids allows for the best possible recapitulation of the human tumor molecular makeup unique to patients with this subtype of CRC. Mouse models allow for an in vivo system that can represent the complexity of a whole organism's response to the presence of a tumor and subsequent treatment. The methodology of this study therefore gives the best chance of reproducibility of my results for clinical treatment for CRC in a promising area of cancer treatment.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
530283
Name
Korver Anneke M
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Epigenetic Combination Therapy in Xenografted Sporadic Microsatellite Instablity-high (MSI-H) Colorectal Cancers
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Animal Modeling; Cancer Stem Cells; Chemotherapy; Colorectal Cancer; Combination Therapy; Epigenetic Gene Silencing; Hypermethlyation; Microsatellite Regions; Patient Derived Organoids; Xenograft
Abstract
Most human cancers exhibit drastic changes in the epigenetic landscape. This has led to the development of drugs that target epigenetic changes in cancers. These drugs have shown promising results in many types of cancer but have yet to be tested in colorectal cancer (CRC). 26,300 Canadians are diagnosed with colorectal cancer and 9,500 die from it every year making it a vital area of research. My project aims to test treatment combinations that specifically target the epigenetic pathway in a subtype of CRC that develops due to DNA methylation-induced gene silencing of key tumor-suppressor genes. I am culturing patient-derived organoids from samples of 10 human CRC patients to create a live CRC model in mice to test novel treatment options. I will compare tumor responses in mice treated with a combination of traditional chemotherapy and a novel epigenetic treatment to those receiving either chemotherapy alone or epigenetic treatments alone. We expect to see that combinatorial treatments will be more effective than either treatment alone. My project thus aims to expand treatment options for CRC, potentially paving the way for personalized medicine approaches.The use of organoids allows for the best possible recapitulation of the human tumor molecular makeup unique to patients with this subtype of CRC. Mouse models allow for an in vivo system that can represent the complexity of a whole organism's response to the presence of a tumor and subsequent treatment. The methodology of this study therefore gives the best chance of reproducibility of my results for clinical treatment for CRC in a promising area of cancer treatment.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Korver, Anneke M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~